Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remdesivir + nirmatrelvir + ritonavir
- Development stage
- Phase 3
- Lead developer
- National Taiwan University Hospital
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination antiviral therapeutic regimen being evaluated by the National Taiwan University Hospital for the treatment of persistent SARS-CoV-2 infection in immunocompromised patients. The regimen consists of an extended 5-day intravenous infusion of remdesivir combined with a 10-day oral course of nirmatrelvir/ritonavir (Paxlovid). Remdesivir is a nucleotide analog that inhibits the viral RNA-dependent RNA polymerase (RdRp), while nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (3CLpro). Ritonavir is co-administered as a pharmacokinetic enhancer that inhibits the cytochrome P450 3A4 (CYP3A4) enzyme, thereby increasing the plasma concentration and half-life of nirmatrelvir. This triple-combination approach is specifically designed to achieve viral clearance in patients who experience prolonged viral shedding and fail to respond to standard short-course antiviral therapies.
- Other names
- Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavirremdesivir + Paxlovid
02
Targets
CYP3A4 (Cytochrome P450 3A4)RdRp (Coronavirus RNA-dependent RNA polymerase)Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on remdesivir + nirmatrelvir + ritonavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remdesivir + nirmatrelvir + ritonavir.